Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6,386 | $4,677 | $2,718 | $3,938 |
| - Cash | $3,035 | $3,605 | $5,374 | $5,236 |
| + Debt | $535 | $675 | $305 | $119 |
| Enterprise Value | $3,886 | $1,747 | -$2,351 | -$1,179 |
| Revenue | $5,604 | $4,015 | $3,754 | $3,564 |
| % Growth | 39.6% | 7% | 5.3% | – |
| Gross Profit | $2,120 | $1,464 | $1,528 | $1,270 |
| % Margin | 37.8% | 36.5% | 40.7% | 35.6% |
| EBITDA | -$695 | -$1,059 | -$625 | -$998 |
| % Margin | -12.4% | -26.4% | -16.6% | -28% |
| Net Income | -$534 | -$1,241 | -$776 | -$928 |
| % Margin | -9.5% | -30.9% | -20.7% | -26% |
| EPS Diluted | -0.32 | -0.76 | -0.63 | -0.63 |
| % Growth | 57.9% | -20.6% | 0% | – |
| Operating Cash Flow | -$95 | -$2,015 | $565 | $354 |
| Capital Expenditures | -$47 | -$106 | -$2 | -$26 |
| Free Cash Flow | -$142 | -$2,121 | $563 | $328 |